

September 3, 2021

## Announcements

### Edward Kaftan, PhD, Appointed Associate Cancer Center Director for Research Affairs

We are pleased to announce the appointment of Edward Kaftan, PhD, to Associate Director Designate for Research Affairs at Yale Cancer Center. On January 1, 2022, Dr. Kaftan will transition to Associate Cancer Center Director for Research Affairs at Yale Cancer Center following the retirement of Robert Garofalo, PhD. Dr. Kaftan has guided our translational science efforts for Yale Cancer Center for nearly a decade, emphasizing an inclusive culture and fostering research engagement and career advancement for our entire Yale Cancer Center community. His proven leadership will be an asset as he begins to lead our Research Affairs team and our Cancer Center Support Grant (CCSG) efforts.



Dr. Kaftan joined Yale School of Medicine in 2012 as an Associate Research Scientist in the Department of Pharmacology, and in 2014 joined the Section of Medical Oncology. For the last seven years, he has worked closely with Roy S. Herbst, MD, PhD, to lead Yale Cancer Center's Translational Research Office; earlier this year, Dr. Kaftan was named Assistant Cancer Center Director for Translational Science. Prior to joining Yale, he worked in research at Wyeth Research, Pfizer Pharmaceuticals, and R.W. Johnson Pharmaceutical Research Institute. He is a graduate of Rensselaer Polytechnic Institute and earned his PhD in Cell Biology from the University of Connecticut.

We are incredibly grateful to Dr. Garofalo for his insight and leadership as Associate Director for Research Affairs for Yale Cancer Center since 2015. He and his team expertly led us through our CCSG renewal in 2018 and have helped to support the exponential growth of our research enterprise. We appreciate Dr. Garofalo's assistance and mentorship over the coming months and look forward to celebrating his retirement prior to his departure in the new year.

Dr. Christi Kim, Joining Waterford

from the desk of  
**Nita Ahuja, MD, MBA, FACS**  
Interim Director, Yale Cancer Center  
Interim Physician-in-Chief,  
Smilow Cancer Hospital

Yale  
NewHaven  
Health  
Smilow Cancer  
Hospital

Yale **CANCER**  
CENTER  
A Comprehensive Cancer Center Designated  
by the National Cancer Institute

## News Center

### Dr. Anna Arnal Estapé Shares Why She Works in Cancer Research



[Read More](#)

[Yale Cancer Center Study Shows Stem-](#)

[Like T Cells Could Aid Immunotherapy in](#)

## Dr. Christi Kim Joining Waterford Care Center

Christi Kim, MD, has been named an Assistant Professor of Clinical Medicine (Medical Oncology) and will join the Smilow Cancer Hospital Care Center in Waterford, CT on October 1. Dr. Kim is a general medical oncologist with special interests in the care of patients with gynecologic cancers, breast cancer, and lymphoma. She received her medical degree from St. George's University School of Medicine and completed both a fellowship and residency at Stony Brook University Hospital, where she joined the faculty as an Assistant Professor of Medicine.



Dr. Kim is an active member of the Gynecologic Oncology Group (GOG) Foundation and of the Society of Gynecologic Oncology (SGO) Clinical Practice Committee. She recently co-authored the SGO clinical practice guideline and has served on advisory boards for The Caris Precision Oncology Alliance Working Group in gynecologic cancer. Dr. Kim has published in several journals including *Blood*, *Journal of the American Society of Nephrology*, and presented ASCO abstracts related to proteinuria with bevacizumab.

## JH Milstone Fund 2021 Awardees Announced

The inaugural awardees of the JH Milstone Fund are **Matthew McConnell, MD**, Instructor of Medicine (Digestive Diseases), and **Sean Gu, MD/PhD**, Clinical Fellow in the Department of Laboratory Medicine (pictured left to right).




Their projects are titled, respectively, *The role of platelets in the pathogenesis of alcohol-related liver disease* and *High-throughput Diagnostic Evaluation of Patients with Platelet Disorders by Mass Cytometry*.

The JH Milstone Fund was established to support early-stage investigators and innovative research and education in thrombosis, thrombolysis, and hemostasis in memory of JH Milstone, MD, by his son, Leonard M. Milstone, MD '70, Professor Emeritus of Dermatology, and daughter-in-law, Ellen B. Milstone, MD '69. Robert Bona, MD, Director of Smilow Cancer Hospital's Benign Hematology Program, and Stephanie Halene, MD, PhD, Chief of Hematology, commented, "The fund, in honor of J. Haskell Milstone, MD, to

support research in blood coagulation, provides important support and encouragement for bright minds to enter this field. We are immensely grateful

## Cancer Treatment



[Read More](#)

## Dr. Natalia Buza Shares Why She Works in Cancer Research



[Read More](#)

## Dr. Manoj Pillai Shares Why He Works in Cancer Research



[Read More](#)

## Yale Cancer Center and Leading Cancer Centers Urge Vaccination to Protect Against HPV and Other Diseases



[Read More](#)

## Dr. Elizabeth Prsic Shares Why She



- **Sandy Morgan, RN**, Patient Services Manager for NP7 at our York Street Campus. Sandy was previously an Assistant Patient Services Manager at the Smilow Cancer Hospital Care Center in Trumbull
- **Samantha Parillo, RN**, Patient Services Manager for Radiation Oncology
- **Ashley Sheldon, RN**, Nursing Professional Development Specialist for our Smilow Cancer Hospital Care Center at Saint Francis Hospital
- **Chloe Shelvin**, Smilow Safety and Quality Coordinator for our York Street Campus

Several faculty in medical oncology will present their expertise in a **Best of Oncology ASCO Direct Conference** next month, including **Lajos Pusztai, MD, DPhil**, Professor of Medicine (Medical Oncology), **Hari Deshpande, MD**, Associate Professor of Medicine (Medical Oncology) and **Aarti Bhatia, MD, MPH**, Assistant Professor of Medicine (Medical Oncology).

## Diversity, Equity, and Inclusion

September is **Women in Medicine Month**, honoring physicians who have offered their time, wisdom, and support to advance women with careers in medicine. Celebrate Women in Medicine Month on Tuesday, September 21, 6:30 – 7:30 AM, with a special **negotiation workshop** presented on YouTube by the American Medical Association by **Anees B. Chagpar, MD, MSc, MPH, MA, MBA, FACS**, the 2020 recipient of the Joan F. Giambalvo Fund for the Advancement of Women. Dr. Chagpar will discuss her research focused on the creation and assessment of a virtual negotiation workshop for women physicians as well as provide tips and advice to guide the negotiation process.

**amplifyHERscience**, a new program of Yale’s Office of Cooperative Research, is inviting applications for a “shark tank” style event on September 23 at 12pm, in which women entrepreneurs will pitch their startup ideas to business professionals. In this case, co-organizers are calling it the Women Innovators from Yale University Dolphin Tank, a “friendly-feedback” session in which participants will receive constructive advice and practical insights following 3 to 5 minute pitches. Presenters must be women. **Applications** to pitch your innovation are due by midnight on September 9. All attendees are welcome regardless of affiliation, industry, or gender. **RSVP to join the audience** at no cost to watch the action live, and for a chance to virtually network.

In a recent piece in the *Journal of the National Comprehensive Cancer Network*, Diversity, Equity, and Representativeness: Coming to Terms With the Henrietta Lacks Act, **Daniel J. Boffa, MD, Keith B. Churchwell, MD**, and **Richard C. Maduka, MD** share how equity in cancer care begins with representativeness in cancer research. The Henrietta Lacks Act was designed to enhance the representativeness of minoritized and traditionally underrepresented populations in the studies that define best practices in cancer care. Their intent in the article was to both discuss the potential impact of the Act on cancer research and cancer care, as well as to offer simple definitions of key terms to encourage more people to engage in the

critical conversations around equity. [Read More](#)

## Employee Profile: Lisa Muscillo



[Read More](#)

Our 3-D mammography and breast imaging van will be at the Uncasville Medical Center at Mohegan Sun on a rotating schedule this fall to provide women with access to the latest breast imaging technology.

To schedule an appointment at the mobile unit, call (203) 688-1010 or 833-772-0003.



[Read More](#)

Dr. Cece Calhoun, a member of the Hematology and Pediatric Oncology Programs at Smilow Cancer Hospital, recently discussed the care of adolescents and young adults with sickle cell disease. Listen on Connecticut Public Radio or download our podcast from iTunes.



[Read More](#)

Our oncology pharmacy team serves as a key member of all multidisciplinary cancer care teams across the entire Smilow Cancer Hospital Network, and includes specialists

## Employee Profile: Lisa Muscillo

They are the people we have all interacted with when arriving to and checking out after a doctor's appointment. The friendly face who is there to greet us after an exam or procedure, and the reassuring voice on the phone who calls to confirm an upcoming appointment. On the fourth floor of the North Haven Medical Center, this person is Lisa Muscillo, one of the many individuals who interacts with patients as they arrive and depart and everything in-between.

Lisa is a Patient Financial Access Specialist. She returns patient phone calls, schedules follow-up appointments, checks patients in and out, and completes referrals. In addition to these responsibilities, Lisa also serves as the key scheduler for hematology-oncology infusions, managing the patients for 10-12 providers on the fourth floor. She schedules biopsies, port placements and removals, secures pre-authorizations for elective chemotherapy admissions, and sets up anywhere from 26-32 infusion chairs every day for chemotherapy and/or platelet infusions.



From the moment she arrives at work, she has no seconds to spare, thriving on the busy pace her job requires but always making time to help coworkers. During the peak of COVID, Lisa maintained her on-site work schedule, adding weekend hours at COVID sites for testing and vaccine administration, and she wouldn't have it any other way. "I'm here to do my job and help patients improve their quality of life," says Lisa. "I'm a people person and I love interacting with our patients; I love our team – they're the bomb, from our doctors to everyone in the lab, to our greeters and transporters, and the support I get from the PFAS team makes very difficult times a lot less stressful."

Denise Armstrong, LCSW, oncology clinical social worker based at North Haven Medical Center says, "Lisa is such a dedicated worker. I admire her tenacity and willingness to ALWAYS put patients first. Lisa is my go-to person for anything work or patient related, always getting back to me right away...I love her work ethic!"

## Recent Publications

Chan RJ, Nekhlyudov L, Duijts SFA, Hudson SV, Jones JM, Keogh J, Love B, Lustberg MB, Mehnert-Theuerkauf A, Nathan P, Ness KK, Sheppard VB, Smith K, Tevaarwerk A, Yu X, Feuerstein M.

### Future Research in Cancer Survivorship.


*Journal of Cancer Survivorship*, Online ahead of print.

### Read More

Stein SI, Soliman MM, Sparapani J, Doustaly R, Cobb BW, Malhotra A, Charalel R, May BJ, Lee KS, **Madoff DC**, Talenfeld AD.


### Conventional Hepatic Volumetry May Lead to Inaccurate Segmental

Hospital Network, and includes specially trained oncology pharmacists, and certified pharmacy techs. They work collaboratively with our physicians and other providers to ensure safe, effective, and timely cancer care. They can also assist with potential high out-of-pocket costs for chemotherapy and cancer care medications, so that patients can focus on their physical and mental health.



### Read More

Diversity in cancer research is critical for success, says Dr. John Onofrey, a member of Yale Cancer Center and Assistant Professor of Radiology & Biomedical Imaging and of Urology. "Optimal solutions cannot be found from looking at one set of data. One must have diverse samples that are representative of life."



### Read More

The Cancer Signaling Networks Research Program welcomes Peter Humphrey, MD, PhD, Professor of Pathology and Director of Genitourinary Pathology. The Cancer Signaling Networks Program brings together world-class investigators across Yale Cancer Center to understand fundamentals of key pathways that drive carcinogenesis and cancer progression, with the goal of enabling development and improvement of effective

### **Yttrium-90 Radiation Dosimetry.**

Cardiovasc Intervent Radiol. 2021 Aug 19. doi: 10.1007/s00270-021-02898-y.  
Online ahead of print.

[Read More](#)

Soble W, Tymon-Rosario J, Huang G.

### **High-risk Endometrial Cancer: The Present and Future of Adjuvant Therapy.**

*touchREVIEWS in Oncology & Haematology*. 2021;17(1):23-27

[Read More](#)

Shammas RL, Fish LJ, Sergesketter AR 2nd, Offodile AC, Phillips BT, Oshima S, Lee CN, Hollenbeck ST, Greenup RA.

### **Dissatisfaction After Post-Mastectomy Breast Reconstruction: A Mixed-Methods Study.**

*Annals of Surgical Oncology*, Online ahead of print.

[Read More](#)

Richman IB, Long JB, Kunst N, Kyanko K, Xu X, Busch S, Gross CP.

### **Trends in Breast Cancer Screening Costs Among Privately Insured Women Aged 40 to 64 Years.**

*JAMA Internal Medicine*, Online ahead of print.

[Read More](#)

Doroshov DB, Wei W, Gupta S, Zugazagoitia J, Robbins C, Adamson B, Rimm DL.

### **PD-L1 Tumor Proportion Score and Overall Survival from First-line Pembrolizumab in Patients with Nonsquamous Versus Squamous Non-Small Cell Lung Cancer.**

*Journal of Thoracic Oncology*, Online ahead of print.

[Read More](#)

Tymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD.

### **DHES0815A, a Novel Antibody-drug Conjugate Targeting HER2/Neu, is Highly Active Against Uterine Serous Carcinomas In Vitro And In Vivo.**

*Gynecologic Oncology*, Online ahead of print.

[Read More](#)

Berger ER, Park T, Saridakis A, Golshan M, Greenup RA, Ahuja N.

### **Immunotherapy Treatment for Triple Negative Breast Cancer.**

*Pharmaceuticals*, 14(8):763.

[Read More](#)

Arora G, Joshi J, Mandal RS, Shrivastava N, Virmani R, Sethi T.

### **Artificial Intelligence in Surveillance, Diagnosis, Drug Discovery and Vaccine Development against COVID-19.**

*Pathogens*, 10(8):1048.

[Read More](#)

Marczyk M, Polańska J, Wojcik A, Lundholm L.


### **Analysis of the Applicability of microRNAs in Peripheral Blood Leukocytes as Biomarkers of Sensitivity and Exposure to Fractionated**

targeted cancer therapeutics. Dr. Humphrey has an extensive background in genitourinary cancer research and has published extensively in prostate pathology and prostate cancer research. In addition to teaching residents and fellows, Dr. Humphrey has demonstrated leadership in program development by starting a genitourinary and renal pathology fellowship program together with Dr. Gilbert Moeckel.



[Read More](#)

According to Dr. Xavier Llor, knowledge is power when it comes to cancer research and knowing your risk of developing cancer. #ThisIsWhy #NothingWillStopUs



[Read More](#)

Our #SmilowStar is Fae Willett, RN, who retired recently after working for 30 years as an Oncology Nurse in the Yale New Haven Health System. Fae is a warrior who survived breast cancer four times and never let her diagnoses or treatment get her down. She is always positive! She continued to be an inspiration to her patients and colleagues and she shared personal experiences with new and active patients, which eased their

**Biopsy as Biomarkers of Sensitivity and Exposure to Fractionated**

**Radiotherapy towards Breast Cancer.**  
*International Journal of Molecular Sciences*, 22(16):8705.

[Read More](#)

Pointer TC, Gorelick FS, Desir GV.

**Renalase: A Multi-Functional Signaling Molecule with Roles in Gastrointestinal Disease.**

*Cells*, 10(8):2006.

[Read More](#)

Uezono H, Nam D, Kluger HM, Sznol M, Hurwitz M, Yu JB, Chiang VL.

**Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases.**

*American Journal of Clinical Oncology*, 44(9):495-501.

[Read More](#)

Leighl NB, Redman MW, Rizvi N, Hirsch FR, Mack PC, Schwartz LH, Wade JL, Irvin WJ, Reddy SC, Crawford J, Bradley JD, Stinchcombe TE, Ramalingam SS, Miao J, Minichiello K, Herbst RS, Papadimitrakopoulou VA, Kelly K, Gandara DR.

**Phase II Study of Durvalumab Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP substudy S1400F, NCT03373760).**

*Journal for ImmunoTherapy of Cancer*, 9(8):e002973.

[Read More](#)

Lopez L 3rd, Dhodapkar M, Gross CP.

**US Nonprofit Hospitals' Community Health Needs Assessments and Implementation Strategies in the Era of the Patient Protection and Affordable Care Act.**

*JAMA Network Open*, 4(8):e2122237.

[Read More](#)

Saridakis A, Berger ER, Harigopal M, Park T, Horowitz N, Le Blanc J, Zanieski G, Chagpar A, Greenup R, Golshan M, Lannin DR.

**Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer.**

*Annals of Surgical Oncology*, Online ahead of print.

[Read More](#)

Liu J, Spakowicz DJ, Ash GI, Hoyd R, Ahluwalia R, Zhang A, Lou S, Lee D, Zhang J, Presley C, Greene A, Stults-Kolehmainen M, Nally LM, Baker JS, Fucito LM, Weinzimer SA, Papachristos AV, Gerstein M.

**Bayesian Structural Time Series for Biomedical Sensor Data: A Flexible Modeling Framework for Evaluating Interventions.**

*PLOS Computational Biology*, 17(8):e1009303, Online ahead of print.

[Read More](#)

Ananth, P.

**Reenvisioning End-of-Life Care Quality Measurement for Adolescents and Young Adults With Cancer—Novel Patient-Centered Indicators and Approaches.**

*JAMA Network Open*, 4(8):e2122323.

[Read More](#)

new and active patients, which eased their fears.

Fae's bubbly personality relaxed our patients. She belongs to a women's chorus, Harmony on the Sound, and always brought music to the treatment area where her patients would sing along with her. Fae spearheaded the annual Making Strides Against Breast Cancer team from Bridgeport Hospital and our Smilow Cancer Hospital Care Centers in Trumbull and Fairfield, along with our families and patients. The teams in Trumbull and Fairfield will miss Fae—she was a joy to work with and loved by all, always putting our patients first and going above and beyond to accommodate them, even if it meant staying beyond her scheduled time.



[Read More](#)

Thank you to Connecticut Sun for their support of breast cancer care at Smilow Cancer Hospital! Team members from The Breast Center at Smilow Cancer Hospital had a great time at last week's game and celebrated with a center court check presentation. — at Mohegan Sun.



[Read More](#)

Azad AA, Armstrong AJ, Alcaraz A, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alekseev B, Iguchi T, Shore ND, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A.

### **Efficacy of Enzalutamide in Subgroups of Men with Metastatic Hormone-sensitive Prostate Cancer Based on Prior Therapy, Disease Volume, and Risk.**

*Prostate Cancer and Prostatic Diseases*, Online ahead of print.

[Read More](#)

Doyle HA, Gee RJ, Masters TD, Gee CR, Booth CJ, Peterson-Roth E, Koski RA, Helfand SC, Price L, Bascombe D, Jackson D, Ho R, Post GR, Mamula MJ.

### **Vaccine-induced ErbB (EGFR/HER2)-specific immunity in Spontaneous Canine Cancer.**

*Translational Oncology*, 14(11):101205, Online ahead of print.

[Read More](#)

Sznol, M.

### **TIL in Melanoma-Similar Approaches, Different Results, Unanswered Questions.**

*Clinical Cancer Research*, Online ahead of print.

[Read More](#)

Vazquez E, Gouraud H, Naudet F, Gross CP, Krumholz HM, Ross JS, Wallach JD.

### **Characteristics of Available Studies and Dissemination of Research Using Major Clinical Data Sharing Platforms.**

*Clinical Trials*, Online ahead of print.

[Read More](#)

Talty R, Bosenberg M.

### **The Role of Ferroptosis in Melanoma.**

*Pigment Cell & Melanoma Research*, Online ahead of print.

[Read More](#)

Kim CS, Turocy T, Moon G, Shine EE, Crawford JM.

### **Escherichia coli-Derived $\gamma$ -Lactams and Structurally Related Metabolites Are Produced at the Intersection of Colibactin and Fatty Acid Biosynthesis.**

*Organic Letters*, Online ahead of print.

[Read More](#)

Chagpar AB, Berger E, Alperovich M, Zanieski G, Avraham T, Lannin DR.

### **ASO Visual Abstract: Assessing Interobserver Variability of Cosmetic Outcome Assessment in Breast Cancer Patients Undergoing Breast Conservation Surgery.**

*Annals of Surgical Oncology*, Online ahead of print.

[Read More](#)

Stein SM, Snider J, Ali SM, Miksad RA, Alexander BM, Castellanos E, Schrock AB, Madison R, Swaminathan A, Venstrom JM, McCusker M.

### **Real-world Association of HER2/ ERBB2 concordance with Trastuzumab Clinical Benefit in Advanced Esophagogastric Cancer.**

*Future Medicine*, Online ahead of print.



[Read More](#)

Adam Brenner, a master's degree candidate at UConn, hosted the inaugural Stuart Brenner Memorial Golf Outing at Lyman Orchards Golf Club in Middlefield, CT on July 31. The tournament, in memory of Adam's father and in gratitude for the extraordinary care received, raised over \$13,000 for our Oncology Social Work Fund. Sonia Grizzle, Executive Director for Smilow Cancer Hospital, accepted the donation on behalf of the oncology social work team and our patients. We are so appreciative of Adam's enormous effort for this very successful event!



[Read More](#)

## **Follow Yale Cancer Center on Twitter**

Follow us on [twitter](#)



New research by [@Joshilabyale](#), [@KelliAConnolly](#) &

[@Krishnaswamylab](#) out today in [@SciImmunology](#) shows certain stem-like T cells could aid #immunotherapy in #cancer treatment.



A #gynpath in [@yalepathology](#), Dr. Natalia Buza helped identify a treatment for an aggressive

[Read More](#)

## Funding and Award Opportunities

### Time-Sensitive Obesity Policy and Program Evaluation (R01)

This FOA establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors and/or weight outcomes to prevent or reduce obesity.

**Application Deadline:** September 22, 2021

[Read More](#)

### Charles H. Hood Foundation: Child Health Research Awards Program

This award is to support newly independent faculty, provide the opportunity to demonstrate creativity, and assist in the transition to other sources of research funding.

**Application Deadline:** September 22, 2021

[Read More](#)

### The Hamoui Foundation/LUNGeVity Award for RET-Positive Lung Cancer Research

The goal of the award is to fund impactful proposals in the RET-positive lung cancer space with direct clinical implications within 1-2 years.

**Application Deadline:** September 17, 2021

[Read More](#)

### RETpositive/LUNGeVity Award for RET-positive Lung Cancer Research

This award supports research that has a direct impact on the outcomes of patients with advanced RET-positive lung cancer; however, innovative proposals that address other unmet needs in the RET-positive lung cancer space are also invited for submission.

**Application Deadline:** September 17, 2021

[Read More](#)

### NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54)

This RFA aims to facilitate institutions in building a community of scientists by recruiting and supporting a cohort of early-career faculty who have demonstrated a commitment to diversity and inclusive excellence.

**Application Deadline:** September 24, 2021

[Read More](#)

### National Comprehensive Cancer Network & Eli Lilly Biomarker Driven Therapy in Lung and Thyroid Cancers

The NCCN and Eli Lilly are seeking proposals to improve patient care and outcomes in lung and thyroid cancers. Multiple factors contribute to the complexity of treating these diseases, including stage and histology, personalization of systemic therapy based on molecular profiles, patient factors, and therapeutic landscape.

**Application Deadline:** September 28, 2021

[Read More](#)

### Cancer Research Institute Irvington Postdoctoral Fellowship Program

treatment for an aggressive #endometrialcancer. She encourages those from diverse backgrounds to pursue #cancerresearch.



"I would like to see that all the knowledge we have gathered translate to our society equitably." —Dr. Anna Arnal Estapé



"Good mentorship, hard work and believing in one's abilities to make a contribution will go a long way to a successful and fulfilling career in cancer research." — Dr. Manoj Pillai



"Cancer research provides continuous challenges and opportunities to learn, and to improve the lives of patients worldwide."- @ElizabethPrsic Director of Adult Inpatient #PalliativeCare



"It is very difficult to be an expert in every aspect of cancer research. It takes a diverse, knowledgeable, persistent team to advance the field of cancer research." Dr. Darryl Martin.



"Beyond an emotional burden, inflated assessments of risk can also lead to harms."—@mleapman editorial discussing #cancer terms that may impact treatment decisions for #prostatecancer.



Only 54% of adolescents are up to date on the HPV vaccination. Today we join @theNCI cancer centers around the country and call for urgent action to get #HPV and other vaccinations back on track.



"What I am happy to see now is that more & more people are talking about this issue, which runs through many institutions in academia." — PamelaKunzMD discusses gender equity in the workforce

with @jamecancerdoc @ASCOPost.



"Diversity in #cancerresearch is critical for success. One must have diverse samples that are representative of life." Dr. John Onofrey



Dr. Daniel Boffa & KChurchwellMD discuss the importance of the

## Cancer Research Institute Livingston Postdoctoral Fellowship Program

Supports qualified young scientists at leading universities and research centers around the world who wish to receive training in fundamental immunology or cancer immunology. Proposals should include studies that directly impact our understanding of the immune system's role in cancer.

**Application Deadline:** October 1, 2021

[Read More](#)

## Technology Development for Single-Molecule Protein Sequencing (R01)

This FOA solicits grant applications to catalyze major advances in single-molecule protein sequencing and single cell proteome analysis through technology development. The goal of this initiative is to achieve technological advances over the next five years that enable generation of protein sequencing data at sufficient scale, speed, cost, and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.

**Application Deadline:** October 1, 2021

[Read More](#)

## Rally Foundation Collaborative Pediatric Cancer Research Awards Program

Rally helps fund the most promising research initiatives, and invests in projects and innovative approaches to research which could lead to advanced studies or clinical trials.

**Application Deadline:** October 1, 2021

[Read More](#)

## The Role of Work in Health Disparities in the U.S. (R01)

The purpose of this FOA is to support innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities, and how work functions as a social determinant of health.

**Application Deadline:** October 5, 2021

[Read More](#)

## Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01)

Through this FOA, the NCI invites R01 grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of these modalities in the characterization of therapy response and/or emergence of treatment resistance.

**Application Deadline:** October 5, 2021

[Read More](#)

## Molecular Imaging of Inflammation in Cancer (R01)

The purpose of this FOA is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation *in vivo*.

**Application Deadline:** October 5, 2021

[Read More](#)

## Cancer Target Discovery and Development (CTD2) (U01)

Through this FOA, the NCI will support the program Cancer Target Discovery and Development. CTD2 is focused on efforts that advance cancer research

discuss the potential impact of the

Henrietta Lacks Enhancing Cancer Research Act @JNCCN "The Act is a good step toward addressing a great need, but few journeys are completed in a single step."

---

## Calendar

### Yale Cancer Answers

**September 5; 7:30 PM**

**NPR**

*Lymphoma and Leukemia Awareness*

Terri Parker, MD

[Learn More](#)

### Genetics Department Seminar Series

**September 7; 11:00 AM**

Janghoo Lim, PhD

[Learn More](#)

### Yale Center for Molecular and Systems Metabolism (YMSM)

**September 7; 11:00 AM**

*Macronutrient Effects on Food Intake and Body Weight Regulation*

Dr. John Speakman

[Learn More](#)

### NCI Blue Ribbon Panel Report Anniversary

**September 9; 12:00 PM**

*Reflections, Progress, and Potential of the Cancer Moonshot*

[Learn More](#)

### Cancer Genetics and Prevention Program

**September 9; 2:30 PM**

*Sharing Genetic Test Results and Cascade Genetic Testing in Families with Known Hereditary Cancer Risk*

Tanaya Shroff, MS, CGC

[Learn More](#)

### Center for GI Cancers Weekly Seminar –

#### Journal Club

**September 9; 4:15 PM**

*PRODIGE-23 Trial*

Justin Persico, MD

[Learn More](#)

### Surgery Grand Rounds

**September 10; 7:30 AM**

*State of the Department AY22*

Nita Abujar, MD, MBA, FACC

and Development. CTDZ is focused on efforts that advance cancer research by bridging the knowledge gap between the large volumes of comprehensive molecular characterizations of many cancer types and studies of the underlying etiology of cancer development, progression, and/or metastasis.

**Application Deadline:** October 6, 2021

[Read More](#)

### **Melanoma Research Alliance RFPs**

The MRA is pleased to announce RFPs for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, staging, and treatment.

**Team Science Award LOI Due:** October 6, 2021

**Young Investigator Award Checklist Due:** November 3, 2021

**Pilot Awards Due:** November 3, 2021

[Read More](#)

### **Metabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01)**

The NCI invites research grant applications for transdisciplinary studies that will enhance our knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation and increased cancer risk as part of the Metabolic Dysregulation and Cancer Risk Program. Through this FOA, the Metabolic Dysregulation and Cancer Risk Program will focus on metabolic dysregulation as the key process linking obesity with cancer risk.

**Application Deadline:** October 6, 2021

[Read More](#)

### **Coordinating Center for the Metabolic Dysregulation and Cancer Risk Program: A Transdisciplinary Approach to Obesity-Associated Cancer Research (U24)**

Through this FOA, the NCI will support a Coordinating Center to facilitate coordination across the consortium of multiple individual research project grants for the Metabolic Dysregulation and Cancer Risk Program whose overarching goal is to enhance our knowledge of the dynamics, and underlying mechanisms, that link obesity, metabolic dysregulation, and increased cancer risk.

**Application Deadline:** October 6, 2021

[Read More](#)

### **Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54)**

The purpose of this FOA is to solicit applications for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54). The overall goal of the CAP-IT Program is to establish an agile and effective network infrastructure to undertake collaborative research focusing on precision cancer prevention and interception, with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations.

**Application Deadline:** October 7, 2021

[Read More](#)

### **Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC) (U24)**

The purpose of this FOA is to solicit Applications for the Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource

Nita Anuja, MD, MBA, FACS  
[Learn More](#)

### **Digestive Diseases Physiopathology Seminar**

**September 10; 1:00 PM**

*Familial Colon Cancer Syndromes*

Xavier Llor, MD, PhD

[Learn More](#)

### **Yale Cancer Answers**

**September 12; 7:30 PM**

NPR

*Ovarian Cancer Awareness Month*

Vaagn Andikyan, MD

[Learn More](#)

### **Genetics Department Seminar Series**

**September 14; 11:30 AM**

Prisca Liberali, PhD

[Learn More](#)

### **Bereavement Seminar**

**September 14; 5:30 PM**

*Understanding and Managing Grief: How Long Am I Going to Feel Like This?*

[Learn More](#)

### **Center for Methods in Implementation and Prevention Science (CMIPS) Seminar Series**

**September 15; 10:00 AM**

*Opportunities and Challenges of Implementation Research to Prevent and Control Noncommunicable Disease in LMICs: The Nepal Experience*

Archana Shrestha, PhD

[Learn More](#)

### **Dissecting Triple Negative Breast Cancer**

**September 15; 1:30 PM**

Lajos Pusztai, MD, DPhil

[Learn More](#)

### **Yale Head and Neck SPORE's Monthly Meeting**

**September 15; 6:00 PM**

[Learn More](#)

### **Pathology Grand Rounds**

**September 16; 12:30 PM**

[Learn More](#)

### **Center for GI Cancers Weekly Seminar**

**September 16; 4:15 PM**

Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC) (U24). The overall goal of this FOA and the companion FOA (U54 CAP-IT Specialized Centers, RFA-CA-21-038) is to establish an agile and effective network infrastructure to undertake collaborative research focusing on precision cancer prevention and interception, with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations.

**Application Deadline:** October 7, 2021

**Read More**

### **Program on the Origins of Gastroesophageal Cancers (R01)**

This FOA is to request applications for the Program on the Origins of Gastroesophageal Cancers (R01). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level.

**Application Deadline:** October 8, 2021

**Read More**

### **Coordinating Center for the Program on the Origins of Gastroesophageal Cancers (U24)**

This FOA is to request applications for the Coordinating Center, Program on the Origins of Gastroesophageal Cancers (U24). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level.

**Application Deadline:** October 8, 2021

**Read More**

### **NCI F99/K00 Predoctoral to Postdoctoral Fellow Transition Award**

This award supports outstanding PhD and other Research Doctoral candidates to complete their dissertation research training (F99 phase) and transition in a timely manner to mentored, cancer-focused postdoctoral career development research positions (K00 phase).

**Letter of Intent Due:** October 10, 2021

**Read More**

### **AACR Anna D. Barker Basic Cancer Research Fellowship**

This award supports postdoctoral or clinical research fellows to establish a successful career path in cancer research.

**Application Deadline:** October 14, 2021

**Read More**

### **CRI Irvington Postdoctoral Fellowship to Promote Racial Diversity**

CRI invites applications from candidates who identify as Black or African American, Hispanic or Latino/a American, or American Indian or Alaska Native. CRI is seeking hypothesis-driven, mechanistic studies in both immunology and tumor immunology that aim to directly impact our understanding of the immune system's role in cancer.

**Application Deadline:** October 21, 2021

**Read More**

**Learn More**

### **Digestive Health Virtual CME Series**

**September 16; 5:00 PM**

*IBD*

Jill Gaidos, MD & Vikram Reddy, MD, PhD,  
FACS, FASCRS

**Learn More**

---

### **Submissions**

Please submit your recent publications, awards, and grant announcements to:

**Renee Gaudette**

Director, Public Affairs and Communications

### **Debbie's Dream Foundation Career Development Award for Gastric Cancer Research**

This award supports junior faculty to conduct gastric cancer research and to establish a successful career path in this field.

**Application Deadline:** October 28, 2021

**Read More**

### **Research Supplements to Promote Re-Entry and Re-integration into Health-Related Research Careers**

The goal of this program is to provide support for a mentored research training experience for individuals with high potential to re-enter or re-integrate into an active research career, after an interruption for family responsibilities or other qualifying circumstances.

**First Available Due Date:** November 1, 2021

**Read More**

### **Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54)**

The purpose of this FOA is to solicit applications for U54 Research Centers to form the Radiation Oncology-Biology Integration Network (ROBIN). The cadre of ROBIN Centers created through this FOA will establish an agile and effective national radiation oncology network infrastructure that collectively address critical hypothesis-based translational research knowledge gaps on the biological basis of responses in cancer patients who undergo radiation treatments.

**Application Deadline:** November 1, 2021

**Read More**

### **Acquired Resistance to Therapy Network (ARTNet; U54)**

The ARTNet FOA is a new funding opportunity that builds upon the Drug Resistance and Sensitivity Network (DRSN, RFA-CA-17-009) to focus study on the mechanistic basis of acquired resistance to cancer therapies and disease recurrence.

**Application Deadline:** November 1, 2021

**Read More**

### **Coordinating and Data Management Center for Acquired Resistance to Therapy Network (ARTNet; U24)**

The overarching goal of the ARTNet is to bridge basic, pre-clinical, and translational research along the tumor-tumor microenvironment continuum to inform new strategies that can be better translated to overcome significant challenges in acquired resistance to cancer therapies. The Coordinating Center will assemble the appropriate infrastructure to facilitate and implement the administrative, outreach, collaborative, and data management activities of the ARTNet.

**Application Deadline:** November 1, 2021

**Read More**

### **Cancer Research Institute Clinical and Laboratory Integration Program (CLIP) Immunotherapy**

CLIP supports pre-clinical and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic. CLIP grants are awarded to qualified scientists exploring clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies.

**Letter of Intent Due:** November 1, 2021

**Read More**

### **Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01)**

The purpose of this FOA is to solicit applications for U01 Research Projects to form the NCI-led PDAC Stromal Reprogramming Consortium (PSRC). The overarching objective of the PSRC is to develop a comprehensive understanding of PDAC tumor progression, its microenvironment (TME) as a tumor fate determinant and the reciprocal tumor-TME interactions that drive clinical outcomes.

**Application Deadline:** November 1, 2021

**Read More**

### **NCI Research Specialist Awards (Laboratory-based Scientist) Award (R50)**

This FOA invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists and is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators.

**Application Deadline:** November 1, 2021

**Read More**

### **NCI Research Specialist (Core-based Scientist) Award (R50)**

This FOA invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists and is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators.

**Application Deadline:** November 1, 2021

**Read More**